Bone Marrow Suppression; Myelosuppression

Bone Marrow Suppression

• Do not give Topotecan Hydrochloride for Injection to patients with baseline neutrophil counts less than 1,500 cells/mm3.
• In order to monitor the occurrence of bone marrow suppression, primarily neutropenia, which may be severe and result in infection and death, monitor peripheral blood cell counts frequently on all patients receiving Topotecan Hydrochloride for Injection.

Myelosuppression

• Topotecan can cause severe myelosuppression. Administer first cycle only to patients with baseline neutrophil counts of greater than or equal to 1,500/mm3 and platelet counts greater than or equal to 100,000/mm3. Monitor blood cell counts.